Patent · US Active

Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes

US10071094B2 · kind B2 · utility

6Cited by

11References

19Claims

0Family size

Inventors

Alan F. List · Tampa, US
David A. Sallman · Tampa, US
John S. Kovach · Rochester, US

Key dates

Filing date	Jul 23, 2015
Grant date	Sep 11, 2018
Priority date	—
Expiry date	Jul 23, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are methods for treating a myelodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.